|
Originally published In Press as doi:10.1074/jbc.M403875200 on April 19, 2004
J. Biol. Chem., Vol. 279, Issue 27, 28419-28425, July 2, 2004
Vpr-mediated Incorporation of UNG2 into HIV-1 Particles Is Required to Modulate the Virus Mutation Rate and for Replication in Macrophages*
Renxiang Chen ,
Erwann Le Rouzic ¶,
Jessica A. Kearney||,
Louis M. Mansky ||**, and
Serge Benichou¶
From the
||Ohio State University Biochemistry Graduate Program, Columbus, Ohio 43210, Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota 55455, and ¶Institut Cochin, Department of Infectious Diseases, INSERM U567, CNRS UMR8104, Paris, France
Human immunodeficiency virus type 1 is able to infect nondividing cells, such as macrophages, and the viral Vpr protein has been shown to participate in this process. Here, we investigated the impact of the recruitment into virus particles of the nuclear form of uracil DNA glycosylase (UNG2), a cellular DNA repair enzyme, on the virus mutation rate and on replication in macrophages. We demonstrate that the interaction of Vpr with UNG2 led to virion incorporation of a catalytically active enzyme that is directly involved with Vpr in modulating the virus mutation rate. The lack of UNG in virions during virus replication in primary monocyte-derived macrophages further exacerbated virus mutant frequencies to an 18-fold increase compared with the 4-fold increase measured in actively dividing cells. Because the presence of UNG is also critical for efficient infection of macrophages, these observations extend the role of Vpr to another early step of the virus life cycle, e.g. viral DNA synthesis, that is essential for replication of human immunodeficiency virus type 1 in nondividing cells.
Received for publication, April 7, 2004
* This research was supported by Public Health Service Grant GM56615 (to L. M. M.) and from the French Agency for AIDS Research and SIDACTION (to S. B. and E. L. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
These authors contributed equally to this work.
** To whom correspondence may be addressed: Institute for Molecular Virology, University of Minnesota, 18-242 Moos Tower, 515 Delaware St. SE, Minneapolis, MN. Tel.: 612-626-5525; Fax: 612-626-5515; E-mail: mansky{at}umn.edu.  To whom correspondence may be addressed: Institut Cochin, INSERM U567, Bâtiment Gustave Roussy, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. Tel.: 33-1-40-51-65-78; Fax: 33-1-40-51-65-70; E-mail: benichou{at}cochin.inserm.fr.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. Romani and S. Engelbrecht
Human immunodeficiency virus type 1 Vpr: functions and molecular interactions
J. Gen. Virol.,
August 1, 2009;
90(8):
1795 - 1805.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Giri, M. Nebozyhn, A. Raymond, B. Gekonge, A. Hancock, S. Creer, C. Nicols, M. Yousef, A. S. Foulkes, K. Mounzer, et al.
Circulating Monocytes in HIV-1-Infected Viremic Subjects Exhibit an Antiapoptosis Gene Signature and Virus- and Host-Mediated Apoptosis Resistance
J. Immunol.,
April 1, 2009;
182(7):
4459 - 4470.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Tan, E. Ehrlich, and X.-F. Yu
DDB1 and Cul4A Are Required for Human Immunodeficiency Virus Type 1 Vpr-Induced G2 Arrest
J. Virol.,
October 1, 2007;
81(19):
10822 - 10830.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Mbisa, R. Barr, J. A. Thomas, N. Vandegraaff, I. J. Dorweiler, E. S. Svarovskaia, W. L. Brown, L. M. Mansky, R. J. Gorelick, R. S. Harris, et al.
Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration
J. Virol.,
July 1, 2007;
81(13):
7099 - 7110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Yang, K. Chen, C. Zhang, S. Huang, and H. Zhang
Virion-associated Uracil DNA Glycosylase-2 and Apurinic/Apyrimidinic Endonuclease Are Involved in the Degradation of APOBEC3G-edited Nascent HIV-1 DNA
J. Biol. Chem.,
April 20, 2007;
282(16):
11667 - 11675.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Begum, N. Izumi, M. Nishikori, H. Nagaoka, R. Shinkura, and T. Honjo
Requirement of Non-canonical Activity of Uracil DNA Glycosylase for Class Switch Recombination
J. Biol. Chem.,
January 5, 2007;
282(1):
731 - 742.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Kaiser and M. Emerman
Uracil DNA Glycosylase Is Dispensable for Human Immunodeficiency Virus Type 1 Replication and Does Not Contribute to the Antiviral Effects of the Cytidine Deaminase Apobec3G
J. Virol.,
January 15, 2006;
80(2):
875 - 882.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. S. R. K. Yedavalli, H.-M. Shih, Y.-P. Chiang, C.-Y. Lu, L.-Y. Chang, M.-Y. Chen, C.-Y. Chuang, A. I. Dayton, K.-T. Jeang, and L.-M. Huang
Human Immunodeficiency Virus Type 1 Vpr Interacts with Antiapoptotic Mitochondrial Protein HAX-1
J. Virol.,
November 1, 2005;
79(21):
13735 - 13746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Schrofelbauer, Q. Yu, S. G. Zeitlin, and N. R. Landau
Human Immunodeficiency Virus Type 1 Vpr Induces the Degradation of the UNG and SMUG Uracil-DNA Glycosylases
J. Virol.,
September 1, 2005;
79(17):
10978 - 10987.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Aukrust, L. Luna, T. Ueland, R. F. Johansen, F. Muller, S. S. Froland, E. C. Seeberg, and M. Bjoras
Impaired base excision repair and accumulation of oxidative base lesions in CD4+ T cells of HIV-infected patients
Blood,
June 15, 2005;
105(12):
4730 - 4735.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|